Mentions
Extended reach
Total likes
Video views
AI synopsis
Overall, the discussions illustrate excitement surrounding the trial of felzartamab, with many users expressing that it offers hope for tackling antibody-mediated rejection in kidney transplants. For example, phrases like 'finally something promising' and inquiries about its potential to be 'the future of transplant' contribute to an optimistic tone, indicating a strong perception of its potential impact on patient care.
Many discussions suggest general support for the findings of the trial, indicating that users see the potential in felzartamab as a treatment option.
The overall interest level is high as participants frequently mention the ongoing discussions and webinars related to the findings.
While the discussions show some depth, including references to safety profiles and trial outcomes, they also hint at a broader conversation rather than an in-depth critique of the methodology.
Posters believe the trial's results could significantly influence future kidney transplantation treatments, calling it a 'game changer' for managing antibody-mediated rejection.
Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection https://t.co/S6wvGwoQqB @ERAkidney | #Nephrology #ERA24 https://t.co/V5eYPDAS9l
In a new trial, researchers assessed the safety, side-effect profile, and preliminary efficacy of felzartamab for the treatment of antibody-mediated kidney-transplant rejection. Read the full trial results and Plain Language Summary: https://t.co/S6wvGwoQqB https://t.co/8GqGC2zpYN
1/10 Welcome to #TenTweetNephJC Have u heard of the new kid on the block for Antibody mediated rejection?“Felzartamab” ! We reviewed data from the phase II trial of this anti CD38 monoclonal antibody
DÖF in Berlin I Felzatamab in AMR Today 8:15 AM at @dgfn_ev #NephrologieKongress 2024 11. Oct @ HOMe https://t.co/7yR1rYhlB3 @MarcusSaemann https://t.co/H3YF5eoM5g
Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection: https://t.co/S6wvGwoQqB Editorial: Felzartamab and Antibody-Mediated Rejection in Kidney Transplants — Hope at Last? https://t.co/q34mOkwYvD #Nephrology https://t.co/HBLgYqCHu3
Interesting results from A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | New England Journal of Medicine
In a special webinar in cooperation between MARKUS HOMe and Nephrology Dialysis and Transplantation, experts discuss landmark studies from the ERA 2024 convention in Stockholm. The focus includes the promising results…
Prof. Georg Böhmi discusses the prognosis with anti-CD38 antibodies in treating antibody-mediated rejection in kidney transplant recipients. This update follows findings from a Phase 2 trial, showing felzartamab's…
We recently conducted a phase 2 randomized trial investigating Felzartamab in patients with late (>180 days) ABMR. https://t.co/ERUmRtlrt3 For this analysis, all patient biopsies were further evaluated using the Molecular Microscope Diagnostic System (@TranscriptomeSI).
RT @MarkusAtHome: TOP 2: Felzartamab in ABMR by Drs. Mayer, @BohmigGeorg et al. https://t.co/qmSAyzzwdm In patients with antibody-mediate…
RT @MarkusAtHome: TOP 2: Felzartamab in ABMR by Drs. Mayer, @BohmigGeorg et al. https://t.co/qmSAyzzwdm In patients with antibody-mediate…
TOP 2: Felzartamab in ABMR by Drs. Mayer, @BohmigGeorg et al. https://t.co/qmSAyzzwdm In patients with antibody-mediated rejection, felzartamab had acceptable safety and side-effect profiles. Check out our webinar about Felzartamab!
https://t.co/eallE643ql https://t.co/mnWyZZmxFl
https://t.co/mnWyZZmxFl https://t.co/eallE643ql
RT @NephJC: 1/10 Welcome to #TenTweetNephJC Have u heard of the new kid on the block for Antibody mediated rejection?“Felzartamab” ! We rev…
RT @NephJC: 1/10 Welcome to #TenTweetNephJC Have u heard of the new kid on the block for Antibody mediated rejection?“Felzartamab” ! We rev…
RT @NephJC: 1/10 Welcome to #TenTweetNephJC Have u heard of the new kid on the block for Antibody mediated rejection?“Felzartamab” ! We rev…
RT @NephJC: 1/10 Welcome to #TenTweetNephJC Have u heard of the new kid on the block for Antibody mediated rejection?“Felzartamab” ! We rev…
RT @NephJC: 1/10 Welcome to #TenTweetNephJC Have u heard of the new kid on the block for Antibody mediated rejection?“Felzartamab” ! We rev…
RT @NephJC: 1/10 Welcome to #TenTweetNephJC Have u heard of the new kid on the block for Antibody mediated rejection?“Felzartamab” ! We rev…
RT @NephJC: 1/10 Welcome to #TenTweetNephJC Have u heard of the new kid on the block for Antibody mediated rejection?“Felzartamab” ! We rev…
RT @NephJC: 1/10 Welcome to #TenTweetNephJC Have u heard of the new kid on the block for Antibody mediated rejection?“Felzartamab” ! We rev…
RT @NephJC: 1/10 Welcome to #TenTweetNephJC Have u heard of the new kid on the block for Antibody mediated rejection?“Felzartamab” ! We rev…
RT @NephJC: 1/10 Welcome to #TenTweetNephJC Have u heard of the new kid on the block for Antibody mediated rejection?“Felzartamab” ! We rev…
RT @NephJC: 1/10 Welcome to #TenTweetNephJC Have u heard of the new kid on the block for Antibody mediated rejection?“Felzartamab” ! We rev…
1/10 Welcome to #TenTweetNephJC Have u heard of the new kid on the block for Antibody mediated rejection?“Felzartamab” ! We reviewed data from the phase II trial of this anti CD38 monoclonal antibody
RT @gunnar_heine: DÖF in Berlin I Felzatamab in AMR Today 8:15 AM at @dgfn_ev #NephrologieKongress 2024 11. Oct @ HOMe https://t.co/7yR1rYh…
RT @gunnar_heine: DÖF in Berlin I Felzatamab in AMR Today 8:15 AM at @dgfn_ev #NephrologieKongress 2024 11. Oct @ HOMe https://t.co/7yR1rYh…
DÖF in Berlin I Felzatamab in AMR Today 8:15 AM at @dgfn_ev #NephrologieKongress 2024 11. Oct @ HOMe https://t.co/7yR1rYhlB3 @MarcusSaemann https://t.co/H3YF5eoM5g
How #NephJC story goes tonight: Antibody mediated rejection in a kidney transplant recipient- A new drug in the pipeline- Will it deliver?
RT @NephJC: How #NephJC story goes tonight: Antibody mediated rejection post kidney transplant- a new drug in the pipeline- will it deliver…
How #NephJC story goes tonight: Antibody mediated rejection post kidney transplant- a new drug in the pipeline- will it deliver?
RT @NephJC: Late night story for Europe! Most probably wouldn't have authors in person tonight. Maybe lure them for chat 2 tomorrow?
RT @NephJC: Late night story for Europe! Most probably wouldn't have authors in person tonight. Maybe lure them for chat 2 tomorrow?
RT @NephJC: Late night story for Europe! Most probably wouldn't have authors in person tonight. Maybe lure them for chat 2 tomorrow?
RT @NephJC: Late night story for Europe! Most probably wouldn't have authors in person tonight. Maybe lure them for chat 2 tomorrow?
Late night story for Europe! Most probably wouldn't have authors in person tonight. Maybe lure them for chat 2 tomorrow?
Descubre los resultados del Felzartamab en el tratamiento del rechazo mediado por anticuerpos ¿Será esta terapia el futuro del trasplante renal ?
RT @NEJM: In a new trial, researchers assessed the safety, side-effect profile, and preliminary efficacy of felzartamab for the treatment o…
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection: https://t.co/S6wvGwoQqB Editorial:…
➡️Up next #NephJC, on Sept 24/25 we will discuss RCT Felzartamab in Antibody-Mediated Rejection pubmed.ncbi.nlm.nih.gov/38804514/ Above X/Tweetorial created by @brian_rifkin
11/10 ➡️Up next - Sept 24/25 join us for some transplant
RT @NephJC: And in 2 weeks join us for some transplant nephrology stuff when we discuss: A Randomized Phase 2 Trial of Felzartamab in Antib…
RT @NephJC: And in 2 weeks join us for some transplant nephrology stuff when we discuss: A Randomized Phase 2 Trial of Felzartamab in Antib…
RT @NephJC: And in 2 weeks join us for some transplant nephrology stuff when we discuss: A Randomized Phase 2 Trial of Felzartamab in Antib…
And in 2 weeks join us for some transplant nephrology stuff when we discuss: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection #NephJC https://t.co/fRpvMvCtmX
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection: https://t.co/S6wvGwoQqB Editorial:…
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | New England Journal of Medicine https://t.co/NzJoZPeQtQ
RT @NEJM: In a new trial, researchers assessed the safety, side-effect profile, and preliminary efficacy of felzartamab for the treatment o…
RT @NEJM: In a new trial, researchers assessed the safety, side-effect profile, and preliminary efficacy of felzartamab for the treatment o…
RT @NEJM: In a new trial, researchers assessed the safety, side-effect profile, and preliminary efficacy of felzartamab for the treatment o…
RT @NEJM: In a new trial, researchers assessed the safety, side-effect profile, and preliminary efficacy of felzartamab for the treatment o…
RT @NEJM: In a new trial, researchers assessed the safety, side-effect profile, and preliminary efficacy of felzartamab for the treatment o…
RT @NEJM: In a new trial, researchers assessed the safety, side-effect profile, and preliminary efficacy of felzartamab for the treatment o…
RT @NEJM: In a new trial, researchers assessed the safety, side-effect profile, and preliminary efficacy of felzartamab for the treatment o…
RT @NEJM: In a new trial, researchers assessed the safety, side-effect profile, and preliminary efficacy of felzartamab for the treatment o…
RT @NEJM: In a new trial, researchers assessed the safety, side-effect profile, and preliminary efficacy of felzartamab for the treatment o…
RT @NEJM: In a new trial, researchers assessed the safety, side-effect profile, and preliminary efficacy of felzartamab for the treatment o…
In a new trial, researchers assessed the safety, side-effect profile, and preliminary efficacy of felzartamab for the treatment of antibody-mediated kidney-transplant rejection. Read the full trial results and Plain Language Summary: https://t.co/S6wvGwoQqB https://t.co/8GqGC2zpYN
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | New England Journal of Medicine https://t.co/6KCNsKLUOi
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection: https://t.co/S6wvGwoQqB Editorial:…
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection: https://t.co/S6wvGwoQqB Editorial:…
RT @ASPNeph: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection #kidneytransplant @NEJM https://t.co/ijhVdzE9TY http…
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection #kidneytransplant @NEJM https://t.co/ijhVdzE9TY https://t.co/myRUFespfQ
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection: https://t.co/S6wvGwoQqB Editorial:…
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection: https://t.co/S6wvGwoQqB Editorial:…
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | New England Journal of Medicine https://t.co/6KCNsKLUOi
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | New England Journal of Medicine https://t.co/Bw8SJgroRK
Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection: https://t.co/S6wvGwoQqB Editorial: Felzartamab and Antibody-Mediated Rejection in Kidney Transplants — Hope at Last? https://t.co/q34mOkwYvD #Nephrology https://t.co/HBLgYqCHu3
RT @Fletcher_RA: Last week I learned that @MatthiasDiebold and team used the Git repository I created for eGFR slope to check & validate th…
RT @Fletcher_RA: Last week I learned that @MatthiasDiebold and team used the Git repository I created for eGFR slope to check & validate th…
RT @Fletcher_RA: Last week I learned that @MatthiasDiebold and team used the Git repository I created for eGFR slope to check & validate th…
RT @JonathanNefro: En trasplante renal con rechazo por anticuerpos agudo y crónico, Felzartamab (anti-CD38), comparado a placebo, fue segur…
RT @Fletcher_RA: Last week I learned that @MatthiasDiebold and team used the Git repository I created for eGFR slope to check & validate th…
RT @Fletcher_RA: Last week I learned that @MatthiasDiebold and team used the Git repository I created for eGFR slope to check & validate th…
Last week I learned that @MatthiasDiebold and team used the Git repository I created for eGFR slope to check & validate the results of their trial of felzartamab for antibody-mediated rejection in @NEJM
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection https://t.co/S6wvGwoQqB @ERAkidney |…
RT @Linkermann_Lab: Awaited data on CD38 inhibition for our ABMR patients. Felzartamab resulted in lower donor-derived cell-free DNA levels…
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection #science #publication #research #journal https://t.co/icDHt0TIjl
Finally hope for our patients with ABMR! Kudos to @schrezenmeier and team!
RT @Ryu04196650Ryu: @NEJM 腎移植後の抗体関連型拒絶反応へのCD38モノクローナル抗体のphase2試験 A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection h…
@NEJM 腎移植後の抗体関連型拒絶反応へのCD38モノクローナル抗体のphase2試験 A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection https://t.co/s7TgamPZSh
RT @JonathanNefro: En trasplante renal con rechazo por anticuerpos agudo y crónico, Felzartamab (anti-CD38), comparado a placebo, fue segur…
RT @JonathanNefro: En trasplante renal con rechazo por anticuerpos agudo y crónico, Felzartamab (anti-CD38), comparado a placebo, fue segur…
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | New England Journal of Medicine https://t.co/doqNyXpX7k
抗CD38抗体が抗体関連型移植拒絶反応に関する第2相試験で良好 https://t.co/zIU3UIQdWD
RT @JonathanNefro: En trasplante renal con rechazo por anticuerpos agudo y crónico, Felzartamab (anti-CD38), comparado a placebo, fue segur…
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection https://t.co/S6wvGwoQqB @ERAkidney |…
RT @JonathanNefro: En trasplante renal con rechazo por anticuerpos agudo y crónico, Felzartamab (anti-CD38), comparado a placebo, fue segur…
Un anti-CD38 prometteur dans le rejet humoral ? Mais avec un effet uniquement suspensif a priori, avec récidive à l'arrêt ⤵️ A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | New England Journal of Medicine https://t.co/sV4oPYr2Zm https://t.co/QiIqOdCalU
Greffe rénale: le #felzartamab montre des premiers signes prometteurs d'efficacité contre le rejet humoral (phase II) https://t.co/rD7Y56nMQe https://t.co/znBdSChaOP
RT @JonathanNefro: En trasplante renal con rechazo por anticuerpos agudo y crónico, Felzartamab (anti-CD38), comparado a placebo, fue segur…
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection https://t.co/S6wvGwoQqB @ERAkidney |…
RT @JonathanNefro: En trasplante renal con rechazo por anticuerpos agudo y crónico, Felzartamab (anti-CD38), comparado a placebo, fue segur…
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection https://t.co/S6wvGwoQqB @ERAkidney |…
We are excited to report the publication of our recent collaborative study with Vienna and Berlin, published in @nejm. @MayerKatherinaa @MatthiasDiebold @kodo_kd @FarsadE https://t.co/xU3pip4yEL
RT @JonathanNefro: En trasplante renal con rechazo por anticuerpos agudo y crónico, Felzartamab (anti-CD38), comparado a placebo, fue segur…
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection https://t.co/S6wvGwoQqB @ERAkidney |…
RT @JochenReiser: Finally something promising for one of the biggest problems in transplantation.
RT @Linkermann_Lab: Awaited data on CD38 inhibition for our ABMR patients. Felzartamab resulted in lower donor-derived cell-free DNA levels…
RT @JochenReiser: Finally something promising for one of the biggest problems in transplantation.
RT @JonathanNefro: En trasplante renal con rechazo por anticuerpos agudo y crónico, Felzartamab (anti-CD38), comparado a placebo, fue segur…
RT @JochenReiser: Finally something promising for one of the biggest problems in transplantation.
Awaited data on CD38 inhibition for our ABMR patients. Felzartamab resulted in lower donor-derived cell-free DNA levels. Congrats to Georg Böhmig/Vienna team, and also the Berlin-team! https://t.co/n15djseHnk
RT @JonathanNefro: En trasplante renal con rechazo por anticuerpos agudo y crónico, Felzartamab (anti-CD38), comparado a placebo, fue segur…
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection #science #publication #research #publications https://t.co/pf3Ik7iVpB
RT @JonathanNefro: En trasplante renal con rechazo por anticuerpos agudo y crónico, Felzartamab (anti-CD38), comparado a placebo, fue segur…
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection https://t.co/S6wvGwoQqB @ERAkidney |…
RT @BohmigGeorg: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | New England Journal of Medicine https://t.co/eQ…
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection https://t.co/S6wvGwoQqB @ERAkidney |…
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | New England Journal of Medicine https://t.co/6KCNsKLUOi
RT @JonathanNefro: En trasplante renal con rechazo por anticuerpos agudo y crónico, Felzartamab (anti-CD38), comparado a placebo, fue segur…
RT @miyatamitsuru: 米Biogen社が115億ドルで米Hi-Bio社を買収した理由です。 https://t.co/2wdhkGdX9k
米Biogen社が115億ドルで米Hi-Bio社を買収した理由です。 https://t.co/2wdhkGdX9k
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection https://t.co/S6wvGwoQqB @ERAkidney |…
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection https://t.co/S6wvGwoQqB @ERAkidney |…
RT @JonathanNefro: En trasplante renal con rechazo por anticuerpos agudo y crónico, Felzartamab (anti-CD38), comparado a placebo, fue segur…
RT @JonathanNefro: En trasplante renal con rechazo por anticuerpos agudo y crónico, Felzartamab (anti-CD38), comparado a placebo, fue segur…
RT @brendonneuen: Icing on the cake for me after a fantastic #ERA24: @MatthiasDiebold let me know the SMART-C GitHub (CREDENCE GFR slope c…
RT @hswapnil: Then we had the anti-CD38 mAB Fertalazamab in ABMR for kidney transplant. Also in @NEJM #ERA24 https://t.co/Y0fnyj56W1 4/
RT @JochenReiser: Finally something promising for one of the biggest problems in transplantation.
Finally something promising for one of the biggest problems in transplantation.
RT @MCrespoBarrio: Interesting results from A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | New England Journal…
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection https://t.co/S6wvGwoQqB @ERAkidney |…
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection https://t.co/S6wvGwoQqB @ERAkidney |…
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection https://t.co/S6wvGwoQqB @ERAkidney |…
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | New England Journal of Medicine https://t.co/eQrW719Ecv
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection https://t.co/S6wvGwoQqB @ERAkidney |…
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection https://t.co/S6wvGwoQqB @ERAkidney |…
Felzartamab tuvo perfiles aceptables de seguridad y efectos secundarios en pacientes con rechazo mediado por anticuerpos. A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection https://t.co/U7yEjjmFmp
$BIIB $MOR #HIBio A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | New England Journal of Medicine https://t.co/loWvReDuee https://t.co/GMPZLZavt1
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection https://t.co/S6wvGwoQqB @ERAkidney |…
RT @MCrespoBarrio: Interesting results from A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | New England Journal…
RT @NEJM: Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection https://t.co/S6wvGwoQqB @ERAkidney |…
Original Article: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection https://t.co/S6wvGwoQqB @ERAkidney | #Nephrology #ERA24 https://t.co/V5eYPDAS9l
RT @MCrespoBarrio: Interesting results from A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | New England Journal…
RT @KSusztak: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | @NEJM https://t.co/s9mamYQ6BR
RT @KSusztak: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | @NEJM https://t.co/s9mamYQ6BR
RT @MCrespoBarrio: Interesting results from A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | New England Journal…
Interesting results from A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | New England Journal of Medicine
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | New England Journal of Medicine https://t.co/bw7bXLaRZ6
RT @KSusztak: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | @NEJM https://t.co/s9mamYQ6BR
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | @NEJM https://t.co/s9mamYQ6BR
DOI: 10.1056/NEJMoa2400763 followed by a 6-month observation period. The primary outcome was the safety and. Copyright © 2024 Massachusetts Medical Society ...
doi: 10.1056/NEJMoa2400763 El tratamiento con felzartamab suprimió la actividad del rechazo mediado por anticuerpos en pacientes con trasplante renal ...
10.1056/NEJMoa2400763. Journal and - The New England Journal of Medicine (NEJM) is a leading medical publication for a wide variety. Authors of medical ...
... 10.1056/NEJMoa2400763 El tratamiento con felzartamab suprimió la actividad del rechazo mediado por anticuerpos en pacientes con trasplante ...
doi: 10.1056/NEJMoa2400763. El tratamiento con felzartamab suprimió la actividad del rechazo mediado por anticuerpos en pacientes con ...
2024;391:122–132. doi: 10.1056/NEJMoa2400763 El tratamiento con felzartamab suprimió la actividad del rechazo mediado por anticuerpos en ...
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection - (https://www.nejm.org/doi/full/10.1056/NEJMoa2400763). Source ...
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2400763. 3. Antibody-mediated rejection: New approaches in prevention and management. Science ...
doi: 10.1056/NEJMoa2400763. PubMed. Mayer KA , A randomized phase 2 trial of felzartamab in antibody-mediated rejection . N Engl J Med 2024 ...
... 10.1056/NEJMoa2400763. Epub 2024 May 25. A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection. Mayer KA, Schrezenmeier E ...
doi: 10.1056/NEJMoa2400763. El tratamiento con felzartamab suprimió la actividad del rechazo mediado por anticuerpos en pacientes con ...
DOI: 10.1056/NEJMoa2400763. loading... Frag die KI. Die experimentelle KI von PZ und PTA-Forum. Die experimentelle KI von PZ und PTA-Forum. Die ...
DOI: 10.1056/NEJMoa2400763. loading... Frag die KI. Die experimentelle KI von PZ und PTA-Forum. Die experimentelle KI von PZ und PTA-Forum. Die ...
N Engl J Med, published online May 25, 2024. doi: 10.1056/NEJMoa2400763].
doi:10.1056/NEJMoa2400763. Get Renal Urology Advisor in Your Inbox. Sign up for the latest news, education, & treatment resource information.
... rejection" N Engl J Med 2024; DOI: 10.1056/NEJMoa2400763. Comment. Please enable JavaScript to view the comments powered by Disqus.
LinkedIn. Quellen Mayer K et al. A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection. doi.org/10.1056/NEJMoa2400763 ...
doi.org/10.1056/nejmoa2400763. Currently rated 5.0 by 2 people. Posted in: Medical Procedure News | Medical Science News | Medical Research ...
... 10.1056/NEJMoa2400763. Stichwörter. Medizin. Forschung. Medikament. Wien. Science. Mensch. Wissenschaft. Gesundheit. Therapien. Krankheiten.
DOI: 10.1056/NEJMoa2400763. Journal information: New England Journal of Medicine. Provided by Medical University of Vienna. + Explore further ...
doi:10.1056/NEJMoa2400763; HI-Bio. HI-Bio Announces Positive Results from Phase 2 Study of Felzartamab for Late Antibody-Mediated Rejection ...
2024;391:122–132. doi: 10.1056/NEJMoa2400763 El tratamiento con felzartamab suprimió la actividad del rechazo mediado por anticuerpos en ...
2024;391:122–132. doi: 10.1056/NEJMoa2400763 El tratamiento con felzartamab suprimió la actividad del rechazo mediado por anticuerpos en ...
doi: 10.1056/NEJMoa2400763 El tratamiento con felzartamab suprimió la actividad del rechazo mediado por anticuerpos en pacientes con ...
doi: 10.1056/NEJMoa2400763 El tratamiento con felzartamab suprimió la actividad del rechazo mediado por anticuerpos en pacientes con ...
2024;391:122–132. doi: 10.1056/NEJMoa2400763 El tratamiento con felzartamab suprimió la actividad del rechazo mediado por anticuerpos en ...
2024;391:122–132. doi: 10.1056/NEJMoa2400763 El tratamiento con felzartamab suprimió la actividad del rechazo mediado por anticuerpos en ...
2024;391:122–132. doi: 10.1056/NEJMoa2400763 El tratamiento con felzartamab suprimió la actividad del rechazo mediado por anticuerpos en ...
doi: 10.1056/NEJMoa2400763 El tratamiento con felzartamab suprimió la actividad del rechazo mediado por anticuerpos en pacientes con ...
N
NC
GH
MB
MD
DV
M
T
CP
NG
H
TC
BM
SM
PD
ST
SS
KG
AC
MS
MR
MF
ME
SM
VM
L
RC
JL
NM
MN
JM
OP
C
M
旅T
D
SN
AN
DM
PP
MH
D
NT
LA
GM
BN
RF
AM
N
LC
YS
R
RC
JD
SE
LA
JA
AG
TO
AC
T
DR
CM
KR
ES
KF
JR
CH
AL
RG
A
C
VG
NP
G
UJ
B
新
MM
WF
RM
NJ
TS
J
D
JP
JJ
BF
DA
OV
GB
MA
NA
BD
KT
AB
DJ
EM
PD
CL
SF
KS